14 August 2018
For every added hour of delay for patients with sepsis, mortality rises by approximately 7%. It has also recently been declared that around a third of all patients are prescribed the wrong initial therapy, further increasing the risk to life. Rapid and accurate identification of bacterial species and their drug resistance is essential, therefore. In this video, Paulo Galiano, CEO and President, Alifax, discusses the company's new innovative light-scattering and FTIR technology, lighting the way towards better patient management and outcomes.